Rubius Therapeutics Inc. [NASDAQ: RUBY] loss -28.26% or -3.16 points to close at $8.02 with a heavy trading volume of 3810998 shares. The company report on February 18, 2021 that Rubius Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference.
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021, at 11:20 a.m. EST.
A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.
It opened the trading session at $11.15, the shares rose to $11.73 and dropped to $6.75, the range by which the price of stock traded the whole day. The daily chart for RUBY points out that the company has recorded 58.81% gains over the past six months. However, it is still -139.4% lower than its most recent low trading price.
If we look at the average trading volume of 1.30M shares, RUBY reached to a volume of 3810998 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Rubius Therapeutics Inc. [RUBY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RUBY shares is $11.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RUBY stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
SVB Leerink have made an estimate for Rubius Therapeutics Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on March 13, 2020. The new note on the price target was released on March 13, 2020, representing the official price target for Rubius Therapeutics Inc. stock. Previously, the target price had yet another raise to $9, while JP Morgan analysts kept a Neutral rating on RUBY stock.
The Average True Range (ATR) for Rubius Therapeutics Inc. is set at 1.44 The Price to Book ratio for the last quarter was 3.75, with the Price to Cash per share for the same quarter was set at 2.74.
Trading performance analysis for RUBY stock
Rubius Therapeutics Inc. [RUBY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -32.43. With this latest performance, RUBY shares dropped by -21.45% in over the last four-week period, additionally plugging by 58.81% over the last 6 months – not to mention a drop of -1.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RUBY stock in for the last two-week period is set at 32.92, with the RSI for the last a single of trading hit 23.39, and the three-weeks RSI is set at 39.11 for Rubius Therapeutics Inc. [RUBY]. The present Moving Average for the last 50 days of trading for this stock 10.22, while it was recorded at 11.10 for the last single week of trading, and 6.76 for the last 200 days.
Rubius Therapeutics Inc. [RUBY]: A deeper dive into fundamental analysis
Return on Total Capital for RUBY is now -40.65, given the latest momentum, and Return on Invested Capital for the company is -39.89. Return on Equity for this stock declined to -49.00, with Return on Assets sitting at -37.41. When it comes to the capital structure of this company, Rubius Therapeutics Inc. [RUBY] has a Total Debt to Total Equity ratio set at 35.38. Additionally, RUBY Total Debt to Total Capital is recorded at 26.13, with Total Debt to Total Assets ending up at 24.57. Long-Term Debt to Equity for the company is recorded at 31.53, with the Long-Term Debt to Total Capital now at 23.29.
Reflecting on the efficiency of the workforce at the company, Rubius Therapeutics Inc. [RUBY] managed to generate an average of -$732,996 per employee.Rubius Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.10 and a Current Ratio set at 7.10.
Rubius Therapeutics Inc. [RUBY]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Rubius Therapeutics Inc. posted -0.6/share EPS, while the average EPS was predicted by analysts to be reported at -0.55/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RUBY.
An analysis of insider ownership at Rubius Therapeutics Inc. [RUBY]
There are presently around $622 million, or 98.80% of RUBY stock, in the hands of institutional investors. The top three institutional holders of RUBY stocks are: FLAGSHIP PIONEERING INC. with ownership of 38,296,526, which is approximately 0% of the company’s market cap and around 5.80% of the total institutional ownership; FMR LLC, holding 11,378,267 shares of the stock with an approximate value of $91.25 million in RUBY stocks shares; and BAILLIE GIFFORD & CO, currently with $37.77 million in RUBY stock with ownership of nearly 10.206% of the company’s market capitalization.
Positions in Rubius Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 39 institutional holders increased their position in Rubius Therapeutics Inc. [NASDAQ:RUBY] by around 2,451,949 shares. Additionally, 42 investors decreased positions by around 723,987 shares, while 15 investors held positions by with 74,380,007 shares. The mentioned changes placed institutional holdings at 77,555,943 shares, according to the latest SEC report filing. RUBY stock had 13 new institutional investments in for a total of 251,404 shares, while 9 institutional investors sold positions of 138,922 shares during the same period.